A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2009
10/29/2009	US20090269388 Allograft bone composition having a gelatin binder
10/29/2009	US20090269385 Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use
10/29/2009	US20090269373 Saposin C-DOPS: A Novel Anti-Tumor Agent
10/29/2009	US20090269366 T cell epitope peptides of 6b11 ovarian cancer anti-idiotypic antibody
10/29/2009	US20090269365 Immunogenic vaccinia peptides and methods of using same
10/29/2009	US20090269363 Method for screening peptides for use in immunotherapy
10/29/2009	US20090269361 Constructs for delivery of therapeutic agents to neuronal cells
10/29/2009	US20090269358 Proteins with Improved Solubility and Methods for Producing and Using Same
10/29/2009	US20090269356 Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
10/29/2009	US20090269350 drug screening; used to identify compounds that act as agonists and antagonists and modulate the expression of the novel PGP synthase
10/29/2009	US20090269349 Antigenic polypeptides
10/29/2009	US20090269346 Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for LRP2 and Uses Thereof
10/29/2009	US20090269342 Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
10/29/2009	US20090269337 Compositions and methods for treating diabetes
10/29/2009	US20090269333 Replikin peptides in rapid replication of glioma cells and in influenza epidemics
10/29/2009	US20090269331 Caspase-8 and inflammation, infection and wound healing
10/29/2009	US20090269327 isolated from Coprinus clastophyllus; for treating celiac disease caused by proline abundant gluten
10/29/2009	US20090269326 nucleic acid molecule which codes for 6-O-sulfatase or N-sulfamidase; degrading monosaccharides or polysaccharides with the molecules; degrading glycosaminoglycan
10/29/2009	US20090269325 using non-anticoagulant sulfated polysaccharides (NASPs) e.g. pentosan polysulfate or heparins as procoagulants for treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder
10/29/2009	US20090269324 Antimicrobial peracid compositions with selected catalase enzymes and methods of use in aseptic packaging
10/29/2009	US20090269320 Variants of pigment epithelium derived factor and uses thereof
10/29/2009	US20090269319 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
10/29/2009	US20090269316 Methods for Using a Three-Dimensional Stromal Tissue to Promote Angiogenesis
10/29/2009	US20090269306 N-terminal modified interferon-alpha
10/29/2009	US20090269305 Novel macrocyclic inhibitors of hepatitis c virus replication
10/29/2009	US20090269304 Methods of treating cancer using il-21 and monoclonal antibody therapy
10/29/2009	US20090269303 Method for treating or preventing conditions by elevation of the adenosine level in an individual
10/29/2009	US20090269302 Human antibodies that bind human il-12 and methods for producing
10/29/2009	US20090269301 Novel Inhibitors of Glutaminyl Cyclase
10/29/2009	US20090269298 Agent for the prevention and treatment of sexually transmitted diseases-i
10/29/2009	US20090269285 Diagnostic And Therapeutic Epitope, And Transgenic Plant
10/29/2009	US20090269283 Method and product for locating an internal bleeding site
10/29/2009	DE202009009905U1 Flüssig-Formulierung von FSH Liquid formulation of FSH
10/29/2009	DE10029404B4 Arzneiformulierung enthaltend Ciclosporin und deren Verwendung Pharmaceutical formulation containing cyclosporine and their use
10/29/2009	CA2727973A1 Peptidyl diacylglycerides
10/29/2009	CA2722306A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha-2a/2b and ribavirin
10/29/2009	CA2722240A1 Tat protein for preventing or treating aids
10/29/2009	CA2722238A1 Liver-specific nucleic acid regulatory elements and methods and use thereof
10/29/2009	CA2722230A1 Dry transglutaminase composition
10/29/2009	CA2722168A1 Isoform-specific insulin analogues
10/29/2009	CA2721582A1 Recombinant deamidated gliadin antigen
10/29/2009	CA2720994A1 Therapeutic use of botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
10/29/2009	CA2720681A1 Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
10/28/2009	EP2112225A1 Recombinant pox virus for immunization against tumor-associated antigens
10/28/2009	EP2112165A2 Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
10/28/2009	EP2112161A2 Peptides that lower blood glucose levels
10/28/2009	EP2112159A2 Immuno-interactive fragments of the alpha C subunit of inhibin
10/28/2009	EP2112157A1 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
10/28/2009	EP2111870A1 Dosages for treatment of anti-erbB2 antibodies
10/28/2009	EP2111868A1 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders
10/28/2009	EP2111867A1 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
10/28/2009	EP2111414A2 Glucagon/glp-1 receptor co-agonists
10/28/2009	EP2111410A2 Peptide inhibitors of metallo- ectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses
10/28/2009	EP2111230A2 Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
10/28/2009	EP2111229A2 Activin-actriia antagonists and uses for treating or preventing breast cancer
10/28/2009	EP2111228A2 Vegf pathway blockade
10/28/2009	EP2111227A1 Macrocyclic hepatitis c protease inhibitors
10/28/2009	EP2111105A1 Method of delaying the onset of clinically definite multiple sclerosis
10/28/2009	EP1753997B1 Photochromic material comprising a proteorhodopsin apoprotein and retinal analog
10/28/2009	EP1718747B1 Stabilized rnas as transfection controls and silencing reagents
10/28/2009	EP1685250B1 Proteins involved in signal transduction
10/28/2009	EP1644030B1 Liquid, aqueous pharmaceutical composition of factor vii polypeptides
10/28/2009	EP1620182B1 Methods for treating sinus headache
10/28/2009	EP1609861B1 Low-molecular weight peptides inhibiting ion channel activity
10/28/2009	EP1572884B1 Dominant negative variants of methionine aminopeptidase 2 (metap2) and clinical uses thereof
10/28/2009	EP1548032B9 Kdr peptides and vaccines comprising the same
10/28/2009	EP1527340B1 Method for identifying substances
10/28/2009	EP1501538B1 Use of alpha-s2 casein precursor-derived peptides
10/28/2009	EP1436003B1 Taci-immunoglobulin fusion proteins
10/28/2009	EP1430082B1 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
10/28/2009	EP1421539B1 Stabilized factor viii with engineered disulfide bonds
10/28/2009	EP1371377B1 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
10/28/2009	EP1346218B1 Tripeptide of fc gamma riia
10/28/2009	EP1282434B1 Method for cell adhesion and wound healing
10/28/2009	EP1214057B1 Vascular coating composition
10/28/2009	EP1181047B2 Composition comprising alkaline sphingomyelinase of bacterial origin for use as a dietetic preparation, food supplement or pharmaceutical product
10/28/2009	EP1150666B1 Gm-csf for the treatment of crohn's disease
10/28/2009	EP1128731B1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
10/28/2009	EP1012232B1 Genetically modified tumor-targeted bacteria with reduced virulence
10/28/2009	EP0983361B1 Bacterial pheromones and uses therefor
10/28/2009	EP0915706B1 Screening methods for compounds useful in the regulation of body weight
10/28/2009	EP0651793B1 Dna sequences used in the production of recombinant human bssl/cel in transgenic non-human mammals, and the produced bssl/cel used in infant formulas
10/28/2009	CN101568552A Collagen peptide composition and food or beverage containing the same
10/28/2009	CN101568550A Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
10/28/2009	CN101568538A Thiophene analogues for the treatment or prevention of flavivirus infections
10/28/2009	CN101568351A Controlled release composition and process
10/28/2009	CN101568350A Lipidized interferon and uses thereof
10/28/2009	CN101568347A Use of eIF-5A to kill multiple myeloma cells
10/28/2009	CN101568346A Hcv ns3 protease inhibitors
10/28/2009	CN101568328A Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
10/28/2009	CN101565703A Eriocheir sinensis Crustin-2 gene and application of recombinant protein thereof
10/28/2009	CN101565462A Large yellow croaker BPI-BN protein, primer and applications thereof in preparing antibiotic drugs
10/28/2009	CN101565452A Immune 7P truncated peptide and application thereof
10/28/2009	CN101564532A Four-scheme medicine preparing method
10/28/2009	CN101564531A Hormone injection capable of adjusting and controlling the puberty start of sow
10/28/2009	CN101564530A Application of Buthus martensii Karsch Martentoxin
10/28/2009	CN100554963C Diagnostic markers for ischemia
10/28/2009	CN100554410C Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration
10/28/2009	CN100554279C Synthetic polysaccharide antigens for immunological intervention in disease
10/28/2009	CN100554278C Human tumor M2-type pyruvate kinase antigen determinant polypeptide and antibody and their application in diagnositic kit

1 ... 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 ... 3163